Analysts take a look at Zafgen Inc (NASDAQ:ZFGN) having this to say.

November 7, 2017 - By Michael Collier

 Analysts take a look at Zafgen Inc (NASDAQ:ZFGN) having this to say.

Zafgen Inc (NASDAQ:ZFGN) Ratings Coverage

Among 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Zafgen Inc had 17 analyst reports since August 25, 2015 according to SRatingsIntel. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. JMP Securities upgraded the stock to “Mkt Outperform” rating in Friday, January 6 report. As per Thursday, October 15, the company rating was maintained by FBR Capital. Canaccord Genuity maintained Zafgen Inc (NASDAQ:ZFGN) on Friday, November 13 with “Buy” rating. The stock has “Market Perform” rating by Cowen & Co on Wednesday, July 20. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Mkt Perform” rating given on Monday, October 19 by JMP Securities. The firm has “Mkt Perform” rating given on Wednesday, July 20 by FBR Capital. The stock of Zafgen Inc (NASDAQ:ZFGN) earned “Hold” rating by Canaccord Genuity on Thursday, March 10. Leerink Swann downgraded the shares of ZFGN in report on Thursday, December 3 to “Mkt Perform” rating. RBC Capital Markets maintained Zafgen Inc (NASDAQ:ZFGN) rating on Thursday, October 15. RBC Capital Markets has “Outperform” rating and $46 target. Below is a list of Zafgen Inc (NASDAQ:ZFGN) latest ratings and price target changes.

About 21,042 shares traded. Zafgen Inc (NASDAQ:ZFGN) has declined 36.39% since November 7, 2016 and is downtrending. It has underperformed by 53.09% the S&P500.

Zafgen, Inc. is a biopharmaceutical company. The company has market cap of $99.49 million. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. It currently has negative earnings. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

More notable recent Zafgen Inc (NASDAQ:ZFGN) news were published by: Globenewswire.com which released: “Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)” on October 12, 2017, also Globenewswire.com with their article: “Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second …” published on May 04, 2017, Globenewswire.com published: “Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of …” on September 12, 2017. More interesting news about Zafgen Inc (NASDAQ:ZFGN) were released by: Seekingalpha.com and their article: “Zafgen’s Second Act” published on May 10, 2017 as well as Globenewswire.com‘s news article titled: “Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph …” with publication date: October 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.